APOC3, ANGPTL3 and lomitapide trials

13 studies from 2013 to 2026, with 3,787 people taking part. Results: 11 lipid or plaque goal met, 2 safety, side effects or genetics. Every summary comes from the trial's PubMed abstract.

All 13 studies

• CORE/CORE22026 · Olezarsen · 1,061 people

  In patients with severe hypertriglyceridemia, olezarsen substantially lowered triglycerides and reduced acute pancreatitis risk compared with placebo, though higher-dose treatment carried more liver enzyme and platelet-related side effects.

  Primary lipid endpoint metAPOC3, ANGPTL3 and lomitapideUS-approved

• CTX310 phase 12025 · CTX310 · 15 people

  A single dose of the CRISPR-Cas9 gene-editing therapy CTX310 was generally well tolerated and produced dose-dependent reductions in ANGPTL3 levels, supporting further clinical development for dyslipidemia.

  Early safety/biomarker dataAPOC3, ANGPTL3 and lomitapideInvestigational

• ESSENCE-TIMI 73b2025 · Olezarsen · 1,349 people

  In patients with moderate hypertriglyceridemia and elevated cardiovascular risk, olezarsen significantly lowered triglyceride levels at 6 months compared with placebo, with similar rates of serious adverse events.

  Primary lipid endpoint metAPOC3, ANGPTL3 and lomitapideUS-approved

• PALISADE2025 · Plozasiran · 75 people

  In patients with persistent chylomicronemia, plozasiran (siRNA against APOC3) sharply lowered triglycerides and reduced acute pancreatitis episodes compared with placebo, with a similar overall adverse event rate but a signal for hyperglycemia in those with prediabetes/diabetes.

  Primary lipid endpoint metAPOC3, ANGPTL3 and lomitapideUS-approved

• PROLONG-ANG32025 · Solbinsiran · 205 people

  In adults with mixed dyslipidaemia on background statin therapy, solbinsiran 400 mg significantly reduced apoB levels compared with placebo and was generally well tolerated, though its effect on cardiovascular outcomes is still unknown.

  Primary lipid endpoint met (400 mg only)APOC3, ANGPTL3 and lomitapideInvestigational

• ARCHES-22024 · Zodasiran · 204 people

  In adults with mixed hyperlipidemia, zodasiran (an RNAi therapy against ANGPTL3) produced significant, dose-dependent reductions in triglycerides and improvements in non-HDL-C, ApoB, and LDL-C compared with placebo, with a signal of transient HbA1c elevation in diabetic patients at the highest dose.

  Primary lipid endpoint metAPOC3, ANGPTL3 and lomitapideInvestigational

• Balance2024 · Olezarsen · 66 people

  In patients with familial chylomicronemia syndrome, olezarsen 80 mg significantly lowered triglycerides and markedly reduced acute pancreatitis episodes compared with placebo, with the 50-mg dose not reaching significance for the triglyceride endpoint.

  Primary lipid endpoint metAPOC3, ANGPTL3 and lomitapideUS-approved

• Bridge-TIMI 73a2024 · Olezarsen · 154 people

  In patients with moderate-to-severe hypertriglyceridemia and elevated cardiovascular risk, monthly olezarsen substantially lowered triglycerides, APOC3, apolipoprotein B, and non-HDL cholesterol compared with placebo, without major safety concerns.

  Primary lipid endpoint metAPOC3, ANGPTL3 and lomitapideUS-approved

• SHASTA-22024 · Plozasiran · 226 people

  Plozasiran markedly and durably lowered triglycerides (with most patients falling below the acute pancreatitis risk threshold) and APOC3 in severe hypertriglyceridemia, with a favorable safety profile, though it raised LDL-C without increasing ApoB and its effect on clinical complications remains unproven.

  Primary lipid endpoint metAPOC3, ANGPTL3 and lomitapideUS-approved

• ELIPSE HoFH2020 · Evinacumab · 65 people

  In patients with homozygous familial hypercholesterolemia already on maximal lipid-lowering therapy, adding evinacumab markedly lowered LDL cholesterol compared with placebo, with similar adverse event rates.

  Primary lipid endpoint metAPOC3, ANGPTL3 and lomitapideUS-approved

• Evinacumab refractory HC2020 · Evinacumab · 272 people

  In patients with refractory hypercholesterolemia despite maximal lipid-lowering therapy, evinacumab substantially and significantly lowered LDL cholesterol compared with placebo, with serious adverse events occurring at variable rates across dose groups.

  Primary lipid endpoint metAPOC3, ANGPTL3 and lomitapideUS-approved

• APPROACH2019 · Volanesorsen · 66 people

  In patients with familial chylomicronemia syndrome, volanesorsen substantially lowered triglyceride and apolipoprotein C-III levels compared with placebo but caused frequent injection-site reactions and thrombocytopenia.

  Primary lipid endpoint metAPOC3, ANGPTL3 and lomitapideNot US-approved (EU)

• Lomitapide phase 3 HoFH2013 · Lomitapide · 29 people

  In patients with homozygous familial hypercholesterolaemia, lomitapide added to existing lipid-lowering therapy substantially lowered LDL cholesterol with durable effect through 78 weeks, though gastrointestinal side effects and reversible liver enzyme elevations were common.

  Primary lipid endpoint metAPOC3, ANGPTL3 and lomitapideUS-approved

Other medicines

• Statins
• Ezetimibe and bile acid binders
• Bempedoic acid
• PCSK9 inhibitors
• Lp(a) medicines
• CETP inhibitors
• Fibrates, omega-3 and niacin
• Genetics and gene editing
• Meta-analyses

Search and filter all 106 studies in the trial database. Education only, not medical advice.